Aug 22, 2024
Enamine Germany Joins the PROXIDRUGS Consortium
We are thrilled to announce that Enamine Germany will be participating in the prestigious PROXIDRUGS project, funded by the Federal Ministry of Education and Research (BMBF) as part of the Clusters4Future initiative. This innovative consortium focuses on developing a new class of therapeutic agents known as "proxidrugs," which have the potential to target proteins previously considered undruggable.
As PROXIDRUGS enters its second implementation phase with a funding of up to €15 million over the next three years, Enamine Germany is eager to begin working alongside our distinguished partners. These include a diverse network of experts from academia and industry, covering the entire value chain from basic research to clinical application.
Our collaboration aims to advance the technology platforms necessary for proxidrug development and contribute to transforming groundbreaking research into practical medical solutions. We look forward to a fruitful partnership and are excited to bring our expertise in chemical synthesis and compound libraries to this promising venture.
For more detailed information, please visit our full announcement.
